DR. SUJAL SHAH MD NPI 1346426566

NPI Information

  • NPI: 1346426566
  • Provider Name: DR. SUJAL SHAH, MD
  • Classification: Internal Medicine - 207RX0202X
  • Specialization: Medical Oncology
  • Entity Type: Individual
  • PECOS Registration: Yes
  • Address: 1630 S CONGRESS AVE STE 200
    PALM SPRINGS, FL
    ZIP 33461
  • Phone: (561) 253-3980

Map and Directions

Get Directions

NPI Details

DR. Sujal Shah, MD is a medical oncology internal medicine in Palm Springs, FL with 24 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Sujal Shah, MD NPI is 1346426566. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: RUSH MEDICAL COLLEGE OF RUSH UNIVERSITY
Graduation Year:2002

The provider's business location address is:

1630 S CONGRESS AVE STE 200
PALM SPRINGS, FL
ZIP 33461-171
Phone: (561) 253-3980
Fax: (561) 253-3985

The NPI 1346426566 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

  • Injection, pembrolizumab, 1 mg (HCPCS:J9271)
  • Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
  • Injection, nivolumab, 1 mg (HCPCS:J9299)
  • Injection, fosaprepitant, 1 mg (HCPCS:J1453)
  • Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
  • Injection, denosumab, 1 mg (HCPCS:J0897)
  • Injection, paclitaxel, 1 mg (HCPCS:J9267)
  • Injection, atezolizumab, 10 mg (HCPCS:J9022)
  • Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
  • Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
  • Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
  • Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
  • Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
  • Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
  • Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
  • Injection, etoposide, 10 mg (HCPCS:J9181)
  • Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
  • Insertion of needle into vein for collection of blood sample (HCPCS:36415)
  • Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
  • Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
  • Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
  • Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
  • Injection, carboplatin, 50 mg (HCPCS:J9045)
  • Injection of additional new drug or substance into vein (HCPCS:96375)
  • Injection, fluorouracil, 500 mg (HCPCS:J9190)
  • Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
  • Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
  • Injection of drug or substance under skin or into muscle (HCPCS:96372)
  • Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
  • Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
  • Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
  • Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
  • Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
  • Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
  • Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
  • Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
  • Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
  • Infusion into a vein for hydration, each additional hour (HCPCS:96361)
  • Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
  • New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
  • Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
  • Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
  • Irrigation of implanted venous access drug delivery device (HCPCS:96523)
  • Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
  • Application of on-body injector for under skin injection (HCPCS:96377)
  • New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
  • Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
  • Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
  • Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
  • Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
  • Collection of blood sample from implanted device (HCPCS:36591)
  • Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
  • Drawing of blood for a medical problem (HCPCS:99195)
  • Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
  • Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
  • New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)

The enumeration date for this NPI number is 1/17/2008 and was last updated on 11/11/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

No. Taxonomy Code Taxonomy Clasification Taxonomy Specialization License Number License State Primary
1207RX0202XInternal MedicineMedical OncologyME119608FLORIDAYes
2207RX0202XInternal MedicineMedical OncologyN1136TEXASNo
3207RX0202XInternal MedicineMedical Oncology15552NEW HAMPSHIRENo

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.

No. Other Provider Identifier Other Provider Identifier Type Other Provider Identifier State Other Provider Identifier Issuer
132001101MEDICAIDNEW HAMPSHIRE

What is NPI?

NPI stands for National Provider Identifier. The NPI is a 10-digit identification number that is completely unique. The NPI number by itself does not contain any identifiable information such as a provider’s speciality or location. The NPI is assigned to individuals or organizacions for their lifespan and it is independent of key provider information type updates like a change of practices, location or speciality.

This page was last updated on: 11/21/2025

NPI Synchronization or Removal

All materials and services on this site are provided on an "as is" and "as available" basis without warranty of any kind. The NPI record is maintained by the National Plan & Provider Enumeration System (NPPES) and anyone may request this information and other NPPES health care provider data from HHS under The Freedom of Information Act (FOIA), Title 5 of the United States Code, section 552. To update the NPI records please contact the NPPES.